Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics

Crinetics Pharmaceuticals, Inc. (CRNX)

Today's Latest Price: $19.33 USD

0.10 (-0.51%)

Updated Nov 21 6:55pm

Add CRNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CRNX Stock Summary

  • Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than merely 1.35% of US equities in our set.
  • With a price/sales ratio of 266.68, Crinetics Pharmaceuticals Inc has a higher such ratio than 98.97% of stocks in our set.
  • As for revenue growth, note that CRNX's revenue has grown -30.15% over the past 12 months; that beats the revenue growth of only 6.31% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Crinetics Pharmaceuticals Inc are SCYX, RETA, FIXX, QURE, and CLSD.
  • Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to
CRNX Daily Price Range
CRNX 52-Week Price Range

CRNX Stock Price Chart More Charts

CRNX Price/Volume Stats

Current price $19.33
Prev. close $19.43
Day low $18.60
Day high $19.83
50-day MA $17.20
200-day MA $21.56
52-week high $36.95
52-week low $14.33
Volume 39,700
Avg. volume 63,143
Dividend yield N/A
Market Cap 468.21M

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.

CRNX Latest News Stream

Event/Time News Detail
Loading, please wait...

CRNX Latest Social Stream

Loading social stream, please wait...

View Full CRNX Social Stream

CRNX Price Returns

1-mo 14.11%
3-mo 14.38%
6-mo -25.11%
1-year -42.04%
3-year N/A
5-year N/A
YTD -35.55%
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8421 seconds.